Essential hypertension (EH) is
Introduction
Essential hypertension (EH) is a condition that causes a greatly increased risk for stroke, heart disease and kidney failure. As such EH is a major public health problem with approximately 20% of the adult population affected in westernized societies. Many physiological abnormalities have been associated with persistent high blood pressure, but the underlying causes have remained difficult to identify. In large number of such studies have been conducted to date and many different genes have been implicated (5-7), although few have been confirmed through replication. Given that hypertension is a primary risk factor for cardiovascular disease (CVD), such as ischaemic heart disease and stroke, the genes implicated in CVD risk should also be considered targets for involvement in EH susceptibility (8) .
Recently, Wald et al. (9) conducted a comprehensive meta-analysis exploring the role of homocysteine in relation to CVD. The conclusions of these researchers was that mild hyperhomocysteinemia is causally associated with risk of heart disease and stroke and that homocysteine lowering therapy, by simple dietary folate supplementation, may reduce risk of CVD. Folate is a cofactor in the remethylation of homocysteine, without which, homocysteine levels in the plasma increase. Folate metabolism is partly governed by the methylenetetrahydrofolate reductase (MTHFR) enzyme which catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (10) . The MTHFR gene has been mapped to the chromosomal region 1p36.3 and is composed of 11 exons (11) . A common mutation of the MTHFR gene is the C to T transition, located at nucleotide 677 (C677T). This results in the amino acid change: alanine to valine. This mutation is associated with increased thermolability and reduced specific activity of the enzyme (mean activity is 65% in the Ala/Val heterozygote and 30% in the Val/Val homozygous state, respectively compared to the mean activity in the Ala/Ala homozygote) (10) . Patients with a deficiency in MTHFR have elevated blood and urinary levels of homocysteine. Thus, The MTHFR C677T, causing mild hyperhomocysteinemia, is an important genetic risk factor for CVD (9) . A recent study has also indicated that the TT genotype is associated with an increased risk of hypertension specifically in males (12) . Alternatively, a large study conducted by Inamoto (13) showed that the TT genotype was associated with hypertension and carotid stenosis in women. The objectives of our study were to employ a powerful case-control association approach to test for a relationship between the MTHFR (C667T) gene variant and EH susceptibility in Caucasians.
Methods

Subject Groups
For this case-control study we utilised an affected group of 250 hypertensive (HT) patients and a carefully age and sex matched control group of 250 normotensive (NT) individuals. All participants of the study were unrelated and of Caucasian origin. Qualified physicians diagnosed hypertension if blood pressure was above 140 mmHg systolic and 95 mmHg diastolic as recorded on at least 3 occasions over a 2-month period prior to the administration of anti-hypertensive medication. Importantly, 72% of the HT patients included in the case group reported that at least 1 parent was hypertensive, 41% of cases had two hypertensive parents. This provides some genetic enrichment for this affected group. NT individuals had no past or current history of hypertension and all had a blood pressure of less than 140/90 mmHg. The demographic variables are listed in Table 1 . The study protocol complied with the Australian Ethics Standards and was approved by the Griffith University Ethics Committee for experimentation on humans. All participants signed informed consent agreements prior to collection of DNA and clinical information.
Genotyping of the MTHFR Gene Variant
DNA was isolated from frozen whole blood, containing ethylene diamine tetra acetic acid (EDTA) or lithium heparin as anticoagulant, by a standard salting out procedure and resuspended in TE (1.0 mol/l Tris-HCl pH 8.0, 0.5 mol/l CaCl2) buffer as previously described (14) . Genomic DNA (40 ng) was amplified by polymerase chain reaction, in a DNA Thermal Cycler (Perkin-Elmer, Norwalk, USA) using the MTHFR primers designed by Frosst et al. (10) (5 -TGAAGGAGAAG GTGTCTGCGGGA-3 for the sense oligonucleotide primer and 5 -AGGACGGTGCGGTGAGAGTG-3 for the antisense primer; synthesized by GeneWorks, Adelaide, Australia) in the following singleplex reaction: 1.75 mmol/l of MgCl2, IX standard polymerase chain reaction (PCR) buffer, 0.2 mmol/l of deoxynucleotide triphosphates (dNTPs), 0.2 µmol/l each of forward and reverse primers, 0.16 g/l of bovin serum albumin (BSA), 1 unit of Taq polymerase (PerkinElmer), 40 ng of genomics DNA, made to a final volume of 25 µl with sterile distilled water. The cycle parameters were as follows: 1 cycle at 95°C for 3 min for an initial denaturation, followed by 35 cycles of denaturation for 1 min at 94°C, primer annealing for 1 min at 65°C, primer extension for 2 min at 72°C and a final extension for 10 min at 72°C (10) . This amplification reaction resulted in the synthesis of a 198-bp fragment.
The MTHFR gene contains a C to T substitutions at nucleotide 677 (10) Data are mean (SD). SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
2.3 µl of sterile water were added to each extension mix at a final volume of 20 µl and samples digested overnight at 37°C. HinfI did not digest the fragment derived from the C allele, whereas HinfI digested the fragment of the same length from the T allele into 175-and 23-bp fragments. These fragments were then electrophoresed by using a 5% ultra-high-resolution agarose gel, stained with ethidium bromide and visualised under ultraviolet (UV) light.
To confirm results, samples were also subjected to a DNA fragment analysis by using a Perkin-Elmer Applied Biosystems 310 Genetic Analyser (Perkin-Elmer). One of the PCR primers (the reverse primer) was labeled with FAM fluorescent dye. Samples were prepared using the same protocols as the restriction fragment length polymorphism (RFLP) analysis and 1 µl of each digest products were added with 8 µl of a mix contained 1,500 µl of formaldehyde and 63 µl of Genescan-350 TAMRA as size standard (Perkin-Elmer). This mixture was denatured for 2 min at 95°C and 2 min at 4°C before running in the Genescan. The size analysis was done with the GeneScan Analysis Software (Applied Biosystems, Foster City, USA).
An independent laboratory technician, blinded to the initial genotype data, performed quality control analysis for both gene variants by repeat PCR and genotyping of a random selection of 50 cases and controls. All genotype discrepancies were rectified or excluded from subsequent data analysis.
Statistical Analysis
The MTHFR C677T genotype and allele frequencies were calculated from observed genotype counts. As a statistical control for systematic genotyping error and/or population stratification, the expected genotype proportions according to the Hardy-Weinberg law were calculated and compared to observed genotypes. Genotype and allele frequencies were initially assessed for association with EH using standard contingency table analysis incorporating the χ 2 test of independence. This analysis produces a χ 2 statistic with 1 or 2 degrees of freedom and corresponding p-values for allele and genotype distributions, respectively. Conditional logistic regression analysis was performed to estimate the main effects of the MTHFR C677T variant on EH susceptibility after adjustment for body mass index (BMI). Risk magnitudes were estimated by calculating odds ratios (OR) with 95% confidence intervals (CI). The conventional α-level of 0.05 was specified as the significance threshold. All the statistical analyses were performed using the SPSS (v10).
Results
The genotype and derived allele frequencies for the MTHFR C677T variant and the results of the χ 2 analyses are shown in Table 2 . The frequency of genotypes in the case and control groups conformed to the expectations under the HardyWeinberg equilibrium law. The prevalence of the T allele and the homozygous TT genotype in the control group was found to be 34% and 10%, respectively. These frequencies are consistent with control groups in other CVD studies of this variant (9) . Comparison of the HT group against the control group showed that the frequency of the T allele was over-represented in the HT group by 6% (40% in the HT group vs. 34% in the control). The distribution of genotypes in the case group was also different to controls, with the TT homozygotes and CT heterozygotes showing frequencies of 14% and 51%, respectively compared to 10% and 48% in the control population. However, these observed allele and genotype differences were not significant at the α-level of 0.05 ( p 0.07 and p 0.174, respectively). Moreover, there were no gender differences observed for the C677T variant ( p>0.05).
BMI is a well-known and significant risk factor for EH. Indeed, the average BMI in our HT case group (28.8) was significantly higher than in NT controls (26.5) ( p<0.001). Therefore, to adjust for BMI, conditional logistic regression (LR) analysis was performed incorporating the MTHFR C677T mutation and BMI as independent variables. Given the allelic trend observed for the T allele in our initial contingency table analysis, the MTHFR risk variable in the LR model was set as the dominant (CT/TT) genotype. Table 3 shows the results of the multivariate analysis. Interestingly, a modest, yet significant, independent effect of the dominant MTHFR genotype (CT/TT) on EH was revealed after adjusting for the effect of BMI (OR 1.57, 95% CI: 1.04-2.37, p 0.03).
Discussion
Over the past decade, a substantial body of evidence has accumulated implicating the MTHFR C677T mutation as a modest genetic risk factor for cardiovascular disease (OR 1.5, p<0.05) (9) . Although hypertension is a primary risk factor for CVD, few studies have examined the MTHFR C677T variant specifically in relation to EH risk. A recent large scale study conducted by Inamoto et al. (13) examined hypertension and carotid atherosclerosis in in over 3,000 Japanese patients. These researchers reported that the TT genotype of the MTHFR gene was associated with an increased risk of hypertension, conferring a small, but significant, risk of 1.5 (13) . A Spanish case-control study of similar size to our present study also detected an association between MTHFR TT genotype but in males with a greater risk ( 2.3) (12) . In contrast, a recent study of CVD in an unrelated group from the Czech Republic examined the MTHFR C677T in 193 patients diagnosed with EH only (15) . The frequency of the T allele was shown to be over-represented in the Czech group affected with EH compared to the healthy control group in this Czech study (38% vs. 33%). These data also indicated an increased prevalence of the dominant genotype group (CT/TT) compared to controls. Neither of these observed differences was significant, although these researchers did not report the BMI-adjusted effect of MTHFR C677T on EH in this study (15) .
It is important to note that the frequency of the MTHFR 677T allele, and indeed EH prevalence, is known to vary substantially among different ethnic populations (16) . It is these differences in gene and disease frequencies that may partly explain the conflicting association results obtained across independent studies. Our study tested the MTHFR C677T variant for association with EH in a Caucasian casecontrol panel from Australia. The results of this work were consistent with the trends reported by Benes et al. (15) , showing that the prevalence of the T allele and its composite genotypes (CT/TT and TT) were increased in the HT group compared to NT controls. Interestingly, the MTHFR C677T considered under a dominant state (CT/TT) appeared to be significantly associated with EH after adjusting for the confounding effect of BMI. Thus, the effect of the T allele on the total EH group was partially masked by the effect of BMI on EH, but removal of the BMI effect (i.e. analysis of less obese subjects) revealed evidence for association between the gene and EH.
As with other studies of MTHFR and CVD phenotypes, our results indicated that the presence of the 677T allele confers only a modest increased risk for EH. It is possible that a more substantial risk may arise from combinations of MTH-FR C677T variant and other genetic and/or environmental factors. Nevertheless, our findings provide evidence that the MTHFR C677T variant, causing mild hyperhomocysteine, may be an independent risk factor for EH. Further studies designed specifically to determine the adjusted risk that the MTHFR gene imposes on EH are now warranted to confirm the MTHFR gene as a risk factor for EH. Such studies should also consider the possibility that variation elsewhere in the MTHFR gene may also contribute to an association with EH. Finally, studies designed to measure plasma levels of homocysteine in lean patients with EH are required to determine the extent to which the MTHFR C677T mutation transfers to a biochemical change in patients affected with this important vascular disorder.
